The United States digital ovulation test kits market size is projected to be valued at US$ 77.4 million in 2023 and is expected to rise to US$ 185.0 million by 2033. The United digital ovulation test kit sales are expected to thrive at a significant CAGR of 9.1% during the forecast period.
The rising incidence of PCOS (polycystic ovary syndrome) amongst women and decreasing fertility rates are anticipated to boost the growth of the digital ovulation test kits market. According to the Centers for Disease Control, 1 out of every eight couples suffers from conceiving problems due to health issues, age, and other associated factors.
This indicates a market need for cost-efficient and accurate digital ovulation test kits. As the digital ovulation test kit provides cost-effective fertility monitoring, its demand is growing.
According to the Centers for Disease Control and Prevention (CDC), in 2019, nearly 6% of married women in the United States aged 15 to 44 years were incapable of conceiving even after trying for one year. Similarly, around 12% of women in the United States aged 15 to 44 years have difficulty conceiving or carrying a pregnancy, irrespective of marital status.
Therefore, the declining fertility rates and growing awareness about ovulation testing are driving the digital ovulation test kits market in the United States High costs, and low accuracy of IVF treatment is other key factor increasing demand for digital ovulation test kit in the country.
An increase in working-class women is expected to increase fertility awareness and the demand for self-contained digital ovulation test kits. The demand is also surging as these women are reluctant to opt for laboratory testing. Working women can maximize their chances of pregnancy by tracking their ovulation cycle and maintaining a healthy lifestyle and weight.
Attribute | Details |
---|---|
United States Digital Ovulation Test Kits Market CAGR | 9.1% |
United States Digital Ovulation Test Kits Market Valuation (2023) | US$ 77.4 million |
United States Digital Ovulation Test Kits Market (2033) | US$ 185.0 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Driven by a higher average age for pregnancy and a declining fertility rate worldwide, the digital ovulation test kits market rose at a 4.1% CAGR registered from 2018 to 2022. Decreasing rates of fertility are a growing concern across the globe, specifically in the United States
According to the report by Future Market Insights, the United States market for digital ovulation test kits is likely to rise at 9.1% CAGR between 2023 and 2033.
Branded test kits remain the top-selling product in the digital ovulation test kits market, accounting for over 83% of the revenue generated by 2031. This is due to increasing e-commerce availability, which has resulted in the increasing demand for branded test kits.
Institutional sales are expected to lead the market over the forecast period, generating a revenue of US$ 95.1 million by 2031 due to increasing fertility awareness and rising demand for ovulation testing in hospitals.
Key manufacturers in the United States have initiated various awareness programs. Including campaigns, medication maintenance, and online education programs for the public to create awareness about women's health, particularly in terms of PCOS and PCOD. Healthcare providers and organizations are teaming up to improve fertility rates across the United States
For instance, in February 2020, Swiss Precision Diagnostics GmbH launched a campaign named ‘Conceiving Hood,' which is designed to de-stigmatize the pre-pregnancy phase by putting control back in women's hands. With this campaign, the company wants to promote the importance of healthcare care before conception by sharing facts and facilities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Women often find difficulty in interpreting test results in the case of line indicator ovulation test kits and digital ovulation test kits. However, these issues are primarily solved through digital offerings, providing direct results easily readable on digital displays.
The results of a feasibility study conducted by Clearblue revealed that using digital devices reduced the chances of errors and misinterpretation by around 70%. Also, Bio-AMD, Inc. introduced the PixoTest technology to make use of the image and lighting sensing module of the mobile device or smartphone to identify the color change reactions on biochemical test strips.
This enables users to monitor fertility disorders. The rapid adoption of digital strip readers for ovulation tests creates a conducive environment for growth. Digital ovulation test kits have rapidly replaced conventional ovulation test kits with line indicators or analog alternatives in the last decade.
Some leading manufacturers are introducing new features to detect two leading fertility hormones using urine samples. For instance, in October 2017, Procter & Gamble launched the Clearblue Connected Ovulation Test System, the first and only ovulation test system to track two unique fertility hormones with connectivity to a smartphone.
It is the only ovulation test kit that accurately detects both the luteinizing hormone and estrogen to determine an extended fertility period. Growing demand for an advanced digital ovulation test is expected to aid long-term growth.
Advancements in fertility monitoring parameters have resulted in the introduction of alternatives to digital ovulation tests, predicting peak fertility periods. For instance, in February 2021, the United States FDA approved the AVA fertility tracking wearable device.
Wearable devices are proven as clinically effective as LH tests in predicting fertilization and ovulation, with additional days of fertility being identified. Thus, the growing scope of adoption for such alternatives is restraining market growth.
Similarly, the high prices of digital ovulation test kits and incidences of product recalls are expected to deter the growth of the United States digital ovulation test kits market.
The launch of technologically advanced products from companies such as Swiss Precision Diagnostics GmbH, Church & Dwight Co, Inc., and Sugentec Inc. has increased the demand for digital ovulation test kits in the United States market. These products have advanced features such as easy Bluetooth connectivity, improved fertility days tracking, and digital strip reader features.
These smart features have made ovulation monitoring easier by using home ovulation test kits. However, these digital devices with advanced features are relatively inexpensive. If local manufacturers successfully launch digital ovulation test kits at a low price, the demand for digital kits may increase again in the United States market.
Based on product type, branded test kits hold the lead, accounting for nearly 85.20% of the market in 2022. The leading players are promoting and marketing their products through various e-commerce sites to bolster demand in the country.
Direct marketing through e-commerce sites thus supports the growth of branded test kits compared to private label test kits. Similarly, key players promote their products in professional, scientific meetings and conferences. This promotional strategy is expected to greatly increase the sale of branded test kits in the coming decade.
The institutional sales segment is expected to contribute a maximum revenue share of more than 54.21% in the United States digital ovulation test kits market in 2022 owing to the ease of availability of digital ovulation test kits in hospital pharmacies and fertility centers.
Its accessibility to consumers and relatively higher chances of available quality products are significant factors driving market growth through the end of 2031.
The competitive landscape in the United States digital ovulation test kits market is characterized by intense competition among key players. Leading market players are investing in research and development activities to develop advanced and technologically innovative products.
The United States digital ovulation test kits market is highly regulated, and companies are required to comply with stringent quality standards and obtain necessary certifications. This regulatory environment creates barriers to entry for new players and provides an advantage to established companies with a strong reputation and compliance track record.
For example, in November 2020, Samplytics Technologies Private Limited announced the Inito Fertility Monitor, a smartphone-connected device that helps to identify up to 6 fertile days and measures two primary fertility hormones - estrogen and luteinizing hormone (LH).
A few of the leading companies operating in the market are Church & Dwight Co., Inc., Swiss Precision Diagnostics GmbH, Sugentech, Inc., Gregory Pharmaceutical Holdings, Inc., iXensor Co., Ltd, Samplytics Technologies Private Limited, Bio-AMD, and others.
As per FMI, over 72% of the market share is currently covered by the top 2 players in the United States
Recent Development
NFI Consumer Healthcare, a manufacturer and distributor of pharmaceutical ointments expanded the agreement with Callitas Health in February 2019. Through this agreement, the company can distribute co-branded products in the United States, such as the over-the-counter ovulation test kit.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | US$ million for Value |
Key Country Covered | The United States |
Key Segments Covered | Product, Distribution Channel |
Key Companies Profiled | Swiss Precision Diagnostics GmbH; Church & Dwight Co., Inc.; Gregory Pharmaceutical Holdings, Inc.; Sugentech, Inc.; iXensor Co. Ltd; Samplytics Technologies Private Limited; Bio-AMD |
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
The market is estimated to record a CAGR of 9.1%.
The United States is estimated to register a growth of 85.20% through 2033.
Institutional sales segment contributes a maximum share in the market.
The branded test kits holds a maximum revenue of the global market share.
From 2018 to 2022, the global market exhibited 4.1% CAGR.
1. Executive Summary 1.1. USA Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033 5.3.1. Branded Test Kits 5.3.2. Private Label Test Kits 5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 6. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033 6.3.1. Institutional Sales 6.3.1.1. Hospital Pharmacies 6.3.1.2. Gynaecology Clinics 6.3.1.3. IVF Clinics 6.3.1.4. Maternity Care Centers 6.3.2. Retail Sales 6.3.2.1. Retail Pharmacies 6.3.2.2. Drug Stores 6.3.2.3. Hypermarkets & Supermarkets 6.3.2.4. Online Sales 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 7. Key Countries Market Analysis 7.1. USA 7.1.1. Pricing Analysis 7.1.2. Market Share Analysis, 2022 7.1.2.1. By Product 7.1.2.2. By Distribution Channel 8. Market Structure Analysis 8.1. Competition Dashboard 8.2. Competition Benchmarking 8.3. Market Share Analysis of Top Players 8.3.1. By Regional 8.3.2. By Product 8.3.3. By Distribution Channel 9. Competition Analysis 9.1. Competition Deep Dive 9.1.1. Swiss Precision Diagnostics GmbH 9.1.1.1. Overview 9.1.1.2. Product Portfolio 9.1.1.3. Profitability by Market Segments 9.1.1.4. Sales Footprint 9.1.1.5. Strategy Overview 9.1.1.5.1. Marketing Strategy 9.1.1.5.2. Product Strategy 9.1.1.5.3. Channel Strategy 9.1.2. Church & Dwight Co., Inc. 9.1.2.1. Overview 9.1.2.2. Product Portfolio 9.1.2.3. Profitability by Market Segments 9.1.2.4. Sales Footprint 9.1.2.5. Strategy Overview 9.1.2.5.1. Marketing Strategy 9.1.2.5.2. Product Strategy 9.1.2.5.3. Channel Strategy 9.1.3. Gregory Pharmaceutical Holdings, Inc. 9.1.3.1. Overview 9.1.3.2. Product Portfolio 9.1.3.3. Profitability by Market Segments 9.1.3.4. Sales Footprint 9.1.3.5. Strategy Overview 9.1.3.5.1. Marketing Strategy 9.1.3.5.2. Product Strategy 9.1.3.5.3. Channel Strategy 9.1.4. Sugentech, Inc. 9.1.4.1. Overview 9.1.4.2. Product Portfolio 9.1.4.3. Profitability by Market Segments 9.1.4.4. Sales Footprint 9.1.4.5. Strategy Overview 9.1.4.5.1. Marketing Strategy 9.1.4.5.2. Product Strategy 9.1.4.5.3. Channel Strategy 9.1.5. iXensor Co. Ltd 9.1.5.1. Overview 9.1.5.2. Product Portfolio 9.1.5.3. Profitability by Market Segments 9.1.5.4. Sales Footprint 9.1.5.5. Strategy Overview 9.1.5.5.1. Marketing Strategy 9.1.5.5.2. Product Strategy 9.1.5.5.3. Channel Strategy 9.1.6. Samplytics Technologies Private Limited 9.1.6.1. Overview 9.1.6.2. Product Portfolio 9.1.6.3. Profitability by Market Segments 9.1.6.4. Sales Footprint 9.1.6.5. Strategy Overview 9.1.6.5.1. Marketing Strategy 9.1.6.5.2. Product Strategy 9.1.6.5.3. Channel Strategy 9.1.7. Bio-AMD 9.1.7.1. Overview 9.1.7.2. Product Portfolio 9.1.7.3. Profitability by Market Segments 9.1.7.4. Sales Footprint 9.1.7.5. Strategy Overview 9.1.7.5.1. Marketing Strategy 9.1.7.5.2. Product Strategy 9.1.7.5.3. Channel Strategy 9.1.8. Hologic, Inc. 9.1.8.1. Overview 9.1.8.2. Product Portfolio 9.1.8.3. Profitability by Market Segments 9.1.8.4. Sales Footprint 9.1.8.5. Strategy Overview 9.1.8.5.1. Marketing Strategy 9.1.8.5.2. Product Strategy 9.1.8.5.3. Channel Strategy 9.1.9. Easy Healthcare Corporation 9.1.9.1. Overview 9.1.9.2. Product Portfolio 9.1.9.3. Profitability by Market Segments 9.1.9.4. Sales Footprint 9.1.9.5. Strategy Overview 9.1.9.5.1. Marketing Strategy 9.1.9.5.2. Product Strategy 9.1.9.5.3. Channel Strategy 9.1.10. ClinicalGuard.com 9.1.10.1. Overview 9.1.10.2. Product Portfolio 9.1.10.3. Profitability by Market Segments 9.1.10.4. Sales Footprint 9.1.10.5. Strategy Overview 9.1.10.5.1. Marketing Strategy 9.1.10.5.2. Product Strategy 9.1.10.5.3. Channel Strategy 10. Assumptions & Acronyms Used 11. Research Methodology
Healthcare
June 2023
REP-GB-6108
342 pages
Explore Healthcare Insights
View Reports